AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 281 min read$BHC

BHC: Revenue and Adjusted EBITDA grew again; FY26 guidance rose as net debt fell $521M

Bausch Health Companies Inc. reported Q3 revenue growth of 10% and 8% organically, with adjusted EBITDA rising 32% to $1.305B. The company raised its FY26 guidance and reduced net debt by $521M, excluding Bausch + Lomb.

Original reporting
tradingview.com
Published Oct 28, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BHC: Revenue and Adjusted EBITDA grew again; FY26 guidance rose as net debt fell $521M — source image
Source · tradingview.com
Decision brief

The 30-second read

$BHCBullishHigh
01

Why it matters

The earnings beat and guidance raise suggest a bullish short‑term outlook for the stock.

02

Market read

The earnings release provides fresh material that can move BHC's share price in after‑hours trading.

03

What to watch

Potential headwinds from regulatory scrutiny or upcoming patent expirations are not addressed.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Bausch Health Companies Inc. released its Q3 earnings, showing revenue and EBITDA growth and a reduction in net debt.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Q3 revenue rose 10% and Adjusted EBITDA grew 32% with FY26 guidance raised and net debt reduced by $521M.

Expected impact

likely upward pressure as investors price in higher revenue growth and lower debt.

Evidence & confidence

Revenue beat expectations, EBITDA expansion, and debt reduction are material fundamentals that typically lift the stock.

Market effects

Sector

Healthcare sector may see modest lift from BHC's strong performance.

Regional

North American markets could benefit from the positive earnings surprise.

Global

Limited to investors tracking mid‑cap pharma stocks.

Counterpoint

What could challenge this read

If the market has already priced in the guidance, the stock may face a short‑term pullback.

Key entities

  • company
    Bausch Health Companies Inc.

    Mid‑cap pharmaceutical company reporting Q3 results.

Read at source← All news

StoryBausch Health posts Q3 2026 earnings beat, raises full‑year outlook and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 29
$BHCMedAI 8/10

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health (BHC) reported Q3 revenue growth in international and Solta Medical segments, with Solta seeing 18% reported growth. The company reduced net debt by $521M in Q3 and announced a $50M share repurchase program. BHC updated its 2026 outlook, expecting 8% revenue growth and 13% adjusted EBITDA growth. Management remains focused on portfolio performance and operational improvements.

finance.yahoo.com2 min
OCT 28
$BHCHighAI 8/10

Bausch: Q3 Earnings Snapshot

Bausch Health Companies Inc. reported Q3 net income of $436 million, or $1.15 per share, with adjusted earnings of $1.77 per share. Revenue was $2.94 billion. Shares are up 12% over the past year, trading at $6.92 on Wednesday.

finance.yahoo.com2 min
OCT 28
$BHCHighAI 9/10

Why is Bausch Health stock surging today?

Bausch Health (BHC) stock rose 11.5% after reporting Q3 2026 earnings of $1.77 per share, beating estimates by $0.50, and revenue of $2.94B, exceeding expectations. The company raised full-year revenue guidance to $10.975B-$11.175B and authorized a $50M share buyback. It also redeemed $643M in debt, improving its balance sheet. The S&P 500 and Nasdaq declined 0.3% and 1.0%, respectively, on the day.

investing.com2 min